FERA Diagnostics & Biologicals announces Heath Landis and Jeff Baxter, recognized sales and marketing leaders in the animal health industry, have recently joined this innovation company to support the adoption of FerAppease® by veterinarians and their beef and dairy producer clients. Launched in 2022 by FERA, FerAppease is a synthetic analog of the active ingredient Maternal Bovine Appeasing Substance (MBAS). MBAS is a naturally occurring substance that is secreted by the skin of the mammary gland of lactating animals, reducing stress in cattle treated. To use FerAppease, no veterinarian prescription nor Veterinary Feed Directive plan is required, and there are no meat or milk withholding requirements.
As the US National Sales Director for FERA, Landis will lead sales force engagement with distribution partners, veterinarians and their beef and dairy producer clientele to position the use of FerAppease in reducing stress in their cattle during times of handling, transportation and commingling. With over 25 years in the animal health industry and previous sales and leadership experience with MULTIMIN USA/Axiota Animal Health, Landis has built strong relationships with key distributor partners, bovine veterinarians and producers in all segments of the beef and dairy industries.
Baxter has 20 years of science-focused marketing experience with multi-national animal health companies and diagnostic startups all focused on the bovine industry assuming the role of Marketing Director for FERA. Most notably launching the Vista® vaccine line for Intervet Inc. (now Merck Animal Health), Baxter collaborated with technical service peers and the research and development team to define new expectations with bovine veterinarians regarding the understanding of immunology and vaccinology.
For more information visit: www.feraah.com.
